STAAR Surgical Company

STAAR Surgical Company is a global medical device company dedicated to ophthalmic surgery, specializing in the design, development, manufacturing, and marketing of implantable lenses for the eye and their companion delivery systems. Its mission is to provide visual freedom to patients, lessening or eliminating their reliance on glasses or contact lenses, and to improve quality of life through premium, minimally invasive implantable lens solutions that preserve the eye's natural anatomy. The company is headquartered in Lake Forest, California.

STAAR Surgical's primary product line consists of Implantable Collamer Lenses (ICLs), marketed under the EVO family of lenses, including EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva. These phakic intraocular lenses are designed for refractive surgery to correct conditions such as myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia, offering an alternative to traditional corrective eyewear and laser-based procedures like LASIK. While the company historically developed foldable intraocular lenses for cataract surgery and glaucoma devices, ICLs now constitute almost all of its revenue. STAAR Surgical markets its products in over 75 countries worldwide.

In recent corporate developments, Alcon terminated its agreement to acquire STAAR Surgical in January 2026. The company reported strong preliminary net sales for Q1 2026, exceeding $90 million, a significant increase year-over-year, largely driven by performance in China. As of February 2026, STAAR Surgical surpassed 4 million ICLs sold globally. Additionally, the U.S. Food and Drug Administration (FDA) expanded the age indication for the EVO ICL to include patients aged 21 to 60. In February 2026, Warren Foust and Deborah Andrews were appointed as Interim Co-CEOs. STAAR Surgical maintains its position as a global leader in implantable phakic intraocular lenses, aiming to be the first choice for doctors and patients seeking visual freedom.